NeOnc Technologies Holdings is trading at $3.25, up +8.33% in pre-market; no new, verified company-specific announcement explaining the October 28 move was identified.

  • The recently reported plan for a proposed 500-patient trial describes a future goal, not completed enrollment or a trial milestone.
  • A search listing shows an October 28 headline about an executive role at NeOnc’s subsidiary, but the linked GlobeNewswire release is dated October 28, 2025, so it does not establish a fresh catalyst for this move.